• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

几何网络分析为接受免疫检查点抑制剂治疗的高级别浆液性卵巢癌患者提供预后信息。

Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors.

作者信息

Elkin Rena, Oh Jung Hun, Liu Ying L, Selenica Pier, Weigelt Britta, Reis-Filho Jorge S, Zamarin Dmitriy, Deasy Joseph O, Norton Larry, Levine Arnold J, Tannenbaum Allen R

机构信息

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

出版信息

NPJ Genom Med. 2021 Nov 24;6(1):99. doi: 10.1038/s41525-021-00259-9.

DOI:10.1038/s41525-021-00259-9
PMID:34819508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8613272/
Abstract

Network analysis methods can potentially quantify cancer aberrations in gene networks without introducing fitted parameters or variable selection. A new network curvature-based method is introduced to provide an integrated measure of variability within cancer gene networks. The method is applied to high-grade serous ovarian cancers (HGSOCs) to predict response to immune checkpoint inhibitors (ICIs) and to rank key genes associated with prognosis. Copy number alterations (CNAs) from targeted and whole-exome sequencing data were extracted for HGSOC patients (n = 45) treated with ICIs. CNAs at a gene level were represented on a protein-protein interaction network to define patient-specific networks with a fixed topology. A version of Ollivier-Ricci curvature was used to identify genes that play a potentially key role in response to immunotherapy and further to stratify patients at high risk of mortality. Overall survival (OS) was defined as the time from the start of ICI treatment to either death or last follow-up. Kaplan-Meier analysis with log-rank test was performed to assess OS between the high and low curvature classified groups. The network curvature analysis stratified patients at high risk of mortality with p = 0.00047 in Kaplan-Meier analysis in HGSOC patients receiving ICI. Genes with high curvature were in accordance with CNAs relevant to ovarian cancer. Network curvature using CNAs has the potential to be a novel predictor for OS in HGSOC patients treated with immunotherapy.

摘要

网络分析方法有可能在不引入拟合参数或变量选择的情况下,对基因网络中的癌症畸变进行量化。本文引入了一种基于网络曲率的新方法,以提供癌症基因网络内变异性的综合度量。该方法应用于高级别浆液性卵巢癌(HGSOC),以预测对免疫检查点抑制剂(ICI)的反应,并对与预后相关的关键基因进行排名。从接受ICI治疗的HGSOC患者(n = 45)的靶向和全外显子测序数据中提取拷贝数改变(CNA)。基因水平的CNA在蛋白质-蛋白质相互作用网络上表示,以定义具有固定拓扑结构的患者特异性网络。使用一种奥利维耶-里奇曲率来识别在免疫治疗反应中可能起关键作用的基因,并进一步对高死亡风险患者进行分层。总生存期(OS)定义为从ICI治疗开始到死亡或最后一次随访的时间。采用Kaplan-Meier分析和对数秩检验来评估高曲率和低曲率分类组之间的OS。在接受ICI的HGSOC患者的Kaplan-Meier分析中,网络曲率分析将高死亡风险患者分层,p = 0.00047。高曲率基因与卵巢癌相关的CNA一致。使用CNA的网络曲率有可能成为接受免疫治疗的HGSOC患者OS的一种新预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/3afa2fe8ca3a/41525_2021_259_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/0f5591d02712/41525_2021_259_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/868b77bbb3e1/41525_2021_259_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/7c1aaade7a2b/41525_2021_259_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/3afa2fe8ca3a/41525_2021_259_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/0f5591d02712/41525_2021_259_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/868b77bbb3e1/41525_2021_259_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/7c1aaade7a2b/41525_2021_259_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5858/8613272/3afa2fe8ca3a/41525_2021_259_Fig4_HTML.jpg

相似文献

1
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors.几何网络分析为接受免疫检查点抑制剂治疗的高级别浆液性卵巢癌患者提供预后信息。
NPJ Genom Med. 2021 Nov 24;6(1):99. doi: 10.1038/s41525-021-00259-9.
2
A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer.一种用于高级别浆液性卵巢癌总生存的稳健基因表达预后特征。
J Oncol. 2019 Nov 7;2019:3614207. doi: 10.1155/2019/3614207. eCollection 2019.
3
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.基线改良格拉斯哥预后评分与接受免疫检查点抑制剂治疗的转移性尿路上皮癌患者的生存情况相关。
Oncologist. 2021 May;26(5):397-405. doi: 10.1002/onco.13727. Epub 2021 Mar 18.
4
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.中性粒细胞与淋巴细胞比值在免疫治疗期间的变化是非线性预测晚期癌症患者结局的指标。
J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546. doi: 10.1007/s00432-019-02982-4. Epub 2019 Jul 31.
5
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.在携带BRCA1基因突变的高级别浆液性卵巢癌患者中具有强大的免疫原性。
J Cell Mol Med. 2018 Aug;22(8):3979-3986. doi: 10.1111/jcmm.13678. Epub 2018 May 31.
6
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.治疗前预后营养指数作为一种新型生物标志物在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中的应用。
Lung Cancer. 2019 Oct;136:45-51. doi: 10.1016/j.lungcan.2019.08.006. Epub 2019 Aug 14.
7
Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.基于免疫微环境和免疫反应评估的高级别浆液性卵巢癌化疗敏感性和预后的模型构建
Cancer Cell Int. 2021 Nov 4;21(1):593. doi: 10.1186/s12935-021-02295-y.
8
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas.一种用于低级别和高级别卵巢浆液性癌分类的数据分析方法。
BMC Genomics. 2018 Nov 27;19(1):841. doi: 10.1186/s12864-018-5177-9.
9
Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.深度学习为高级别浆液性卵巢癌的复发预测提供了一种新的基于计算机断层扫描的预后生物标志物。
Radiother Oncol. 2019 Mar;132:171-177. doi: 10.1016/j.radonc.2018.10.019. Epub 2018 Nov 1.
10
Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.立体定向放疗联合免疫治疗或靶向治疗转移性肾细胞癌。
BJU Int. 2021 Jun;127(6):703-711. doi: 10.1111/bju.15284. Epub 2020 Nov 19.

引用本文的文献

1
Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancer.与肿瘤信息指导的突变追踪相比,改进的肿瘤类型信息指导在检测上皮性卵巢癌的循环肿瘤DNA及评估微小残留病方面更具优势。
J Exp Clin Cancer Res. 2025 Jun 12;44(1):174. doi: 10.1186/s13046-025-03433-4.
2
ABCB1 confers resistance to carboplatin by accumulating stem-like cells in the G2/M phase of the cell cycle in p53 ovarian cancer.ABCB1通过在p53基因缺失的卵巢癌细胞周期的G2/M期积累干细胞样细胞,赋予对卡铂的抗性。
Cell Death Discov. 2025 Apr 2;11(1):132. doi: 10.1038/s41420-025-02435-7.
3

本文引用的文献

1
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.在人类非小细胞肺癌中进行共享 T 细胞特异性的全局分析,可实现 HLA 推断和抗原发现。
Immunity. 2021 Mar 9;54(3):586-602.e8. doi: 10.1016/j.immuni.2021.02.014.
2
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.遗传定义的卵巢癌同基因小鼠模型作为联合免疫疗法发现的工具。
Cancer Discov. 2021 Feb;11(2):384-407. doi: 10.1158/2159-8290.CD-20-0818. Epub 2020 Nov 6.
3
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
ORCO: Ollivier-Ricci Curvature-Omics-an unsupervised method for analyzing robustness in biological systems.
ORCO:奥利维耶 - 里奇曲率 - 组学——一种用于分析生物系统稳健性的无监督方法。
Bioinformatics. 2025 Mar 4;41(3). doi: 10.1093/bioinformatics/btaf093.
4
Establishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79.新型高级别浆液性卵巢癌细胞系OVAR79的建立
Int J Mol Sci. 2024 Dec 10;25(24):13236. doi: 10.3390/ijms252413236.
5
Insights into targeting LKB1 in tumorigenesis.对肿瘤发生过程中靶向LKB1的见解。
Genes Dis. 2024 Aug 28;12(2):101402. doi: 10.1016/j.gendis.2024.101402. eCollection 2025 Mar.
6
Comparative transcriptomic, epigenomic and immunological analyses identify drivers of disparity in high-grade serous ovarian cancer.比较转录组学、表观基因组学和免疫学分析确定了高级别浆液性卵巢癌差异的驱动因素。
NPJ Genom Med. 2024 Dec 2;9(1):64. doi: 10.1038/s41525-024-00448-2.
7
Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review.解析晚期卵巢癌中免疫检查点抑制剂的潜在生物标志物:一项综述
Invest New Drugs. 2024 Dec;42(6):728-738. doi: 10.1007/s10637-024-01478-4. Epub 2024 Oct 21.
8
ORCO: Ollivier-Ricci Curvature-Omics - an unsupervised method for analyzing robustness in biological systems.ORCO:奥利维耶 - 里奇曲率 - 组学——一种用于分析生物系统稳健性的无监督方法。
bioRxiv. 2024 Oct 11:2024.10.06.616915. doi: 10.1101/2024.10.06.616915.
9
Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.新型蛋白预后标志物与卵巢癌免疫治疗疗效相关。
J Ovarian Res. 2024 Sep 28;17(1):190. doi: 10.1186/s13048-024-01518-w.
10
Charting cellular differentiation trajectories with Ricci flow.利用 Ricci 流绘制细胞分化轨迹。
Nat Commun. 2024 Mar 13;15(1):2258. doi: 10.1038/s41467-024-45889-6.
基于基因定义的同基因类器官平台,用于开发卵巢癌联合治疗方法。
Cancer Discov. 2021 Feb;11(2):362-383. doi: 10.1158/2159-8290.CD-20-0455. Epub 2020 Nov 6.
4
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.常见实体瘤患者中高肿瘤突变负担的流行情况及其与生存的关系。
JAMA Netw Open. 2020 Oct 1;3(10):e2025109. doi: 10.1001/jamanetworkopen.2020.25109.
5
Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.复发性卵巢癌中的突变、同源DNA修复缺陷、肿瘤突变负荷及对免疫检查点抑制的反应
JCO Precis Oncol. 2020 Jun 16;4. doi: 10.1200/PO.20.00069. eCollection 2020.
6
p53: 800 million years of evolution and 40 years of discovery.p53:8 亿年的进化与 40 年的发现。
Nat Rev Cancer. 2020 Aug;20(8):471-480. doi: 10.1038/s41568-020-0262-1. Epub 2020 May 13.
7
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.奥拉帕利联合 PD-L1 抑制剂度伐利尤单抗治疗复发性卵巢癌:概念验证性 II 期研究。
Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12.
8
A reference map of the human binary protein interactome.人类二进制蛋白质相互作用组参考图谱。
Nature. 2020 Apr;580(7803):402-408. doi: 10.1038/s41586-020-2188-x. Epub 2020 Apr 8.
9
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.随机 II 期试验:纳武利尤单抗对比纳武利尤单抗联合伊匹单抗用于复发性或持续性卵巢癌:NRG 肿瘤学研究。
J Clin Oncol. 2020 Jun 1;38(16):1814-1823. doi: 10.1200/JCO.19.02059. Epub 2020 Apr 10.
10
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.免疫基因组分析确定卵巢癌中联合 PARP 和 PD-1 抑制的反应。
Nat Commun. 2020 Mar 19;11(1):1459. doi: 10.1038/s41467-020-15315-8.